Anticoagulant Reversal Drugs Market is Projected to Expand at a CAGR of 14.4%, US$ 2.20 Billion By 2028

The global anticoagulant reversal drugs market size is expected to reach USD 2.20 billion by 2028 according to a new study by Polaris Market Research.

Most common bleeding disorders include hemophilia A and B, and Von Willebrand disease (VWD). As per the data published by the National Hemophilia Foundation (NHF), in the U.S alone, more than 30,000 to 33,000 million people are suffering from hemophilia, and around 60% were accounted for the lethal form.

VWD is one of the common forms affecting one in every 100 people. Such bleeding disorders affect blood clotting and are expected to result in excessive bleeding both inside and outside the body. This extensive bleeding can cause death in individuals and necessitates the use of anticoagulant reveral drugs.

Get an exclusive sample PDF report of Anticoagulant Reversal Drugs Market @ https://www.polarismarketresearch.com/industry-analysis/anticoagulant-reversal-drugs-market/request-for-sample

Certain surgeries such as atrial fibrillation, ischemic stroke, pulmonary embolism, heart-related ailments, and deep vein thrombosis require anticoagulants. As per the estimates of the CDC, over 2% of the people aged below 65 years suffer from atrial fibrillation, while 9% aged above 65 years usually develop this condition. It is also predicted that by 2030 around 12.1 million people will develop such conditions. It is also being estimated that around 60,000-100,000 U.S. individuals suffer die from deep vein thrombosis.

North America market accounted for the highest revenue share in 2020 and is expected to maintain its dominance over the forecast period. This can be attributed to the easy availability of the anticoagulant reversal drugs, high consumer expenditure in the healthcare sector, and favorable healthcare-related policies for consumers in U.S. and Canada.

However, Asia Pacific anticoagulant reversal drugs industry is projected to witness the fastest market growth rate over the study period. This growth is due to growing cases of bleeding disorders in the huge population in emerging economies.

Moreover, increased medical attention and awareness of the disease among individuals also supporting the region's market growth. Increased attention of the key players in the market in the booming region also complemented its market growth for anticoagulant reversal drugs.

Market participants such Portola Pharmaceuticals, CSL Behring, Bausch Health Companies Inc., Alps Pharmaceutical Ind. Co., Ltd, Boehringer Ingelheim, Octapharma AG, AMAG Pharmaceuticals, Inc., Pfizer, Inc., Dr. Reddy's Laboratories, SG Pharma Pvt Ltd., and Fresenius Kabi AG.

For In-depth Information Enquire Before Purchasing This Report @ https://www.polarismarketresearch.com/industry-analysis/anticoagulant-reversal-drugs-market/inquire-before-buying

Polaris Market Research has segmented the anticoagulant reversal drugs market report on the basis of product, distribution channel and region:

Anticoagulant Reversal Drugs, Product Outlook (Revenue - USD Million, 2016 - 2028)
• Prothrombin Complex Concentrates
• Phytonadione
• Andexanet Alfa
• Idarucizumab
• Protamine
• Others

Anticoagulant Reversal Drugs, Distribution Channel Outlook (Revenue - USD Million, 2016 - 2028)
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Buy Now @ https://www.polarismarketresearch.com/checkouts/8361

Contact Us:

Polaris Market Research
Email: sales@polarismarketresearch.com
Ph: +1-929 297-9727
Web: https://www.polarismarketresearch.com

About Us:

Polaris Market Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Polaris Market Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We at Polaris are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures, present globally.

This release was published on openPR.